Traws Pharma (TRAW) Return on Sales (2016 - 2025)
Traws Pharma (TRAW) has disclosed Return on Sales for 14 consecutive years, with 3.28% as the latest value for Q3 2025.
- On a quarterly basis, Return on Sales rose 14648.0% to 3.28% in Q3 2025 year-over-year; TTM through Sep 2025 was 3.28%, a 62308.0% increase, with the full-year FY2024 number at 629.97%, down 54016.0% from a year prior.
- Return on Sales was 3.28% for Q3 2025 at Traws Pharma, up from 4.76% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 3.28% in Q3 2025 to a low of 2164.0% in Q2 2024.
- A 5-year average of 216.42% and a median of 81.49% in 2021 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: crashed -208312bps in 2024, then skyrocketed 215924bps in 2025.
- Traws Pharma's Return on Sales stood at 67.2% in 2021, then crashed by -52bps to 102.39% in 2022, then grew by 22bps to 79.68% in 2023, then fell by -18bps to 94.25% in 2024, then skyrocketed by 97bps to 3.28% in 2025.
- Per Business Quant, the three most recent readings for TRAW's Return on Sales are 3.28% (Q3 2025), 4.76% (Q2 2025), and 604.24% (Q1 2025).